Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.49 |
| ▸ | TACR1 | P25103 | 1/20 | 0.45 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.45 |
| ▸ | TLR9 | Q9NR96 | 4/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.44 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.44 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.44 |
| ▸ | GHSR | Q92847 | 3/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17368686 | 0.90 | TACR1 (0.45) | YAP1TACR1OPRD1OPRK1TLR9 | |
| SCHEMBL31166827 | 0.90 | YAP1 (0.46) | YAP1TLR9GPR119PRMT5TLR7 | |
| SCHEMBL2475638 | 0.90 | YAP1 (0.46) | YAP1TLR9GPR119PRMT5TLR7 | |
| SCHEMBL2477870 | 0.88 | L3MBTL1 (0.52) | OPRD1OPRK1PRMT5 | |
| SCHEMBL8316171 | 0.88 | MEN1 (0.47) | OPRD1OPRK1 | |
| SCHEMBL18656530 | 0.86 | S1PR5 (0.45) | — | |
| SCHEMBL4672807 | 0.84 | OPRD1 (0.53) | YAP1TACR1OPRD1OPRK1GPR119 | |
| SCHEMBL8398896 | 0.84 | YAP1 (0.49) | YAP1TACR1OPRD1OPRK1TLR9 | |
| SCHEMBL2582728 | 0.84 | TACR1 (0.51) | YAP1TACR1OPRD1OPRK1GPR119 | |
| SCHEMBL15959935 | 0.82 | GPR119 (0.47) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9650337-B2 | Method of synthesising 4-piperidin-4-yl-benzene-1,3-diol and the salts of same and novel compound tert-butyl 4-(2,4-dihydroxy-phenyl)-4-hydroxy-piperidine-1-carboxylate | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2017-05-16 | — | — | US | disclosed |
| EP-2956438-B1 | METHOD FOR SYNTHESISING 4-PIPERIDIN-4-YL-BENZENE-1,3-DIOL AND THE SALTS OF SAME AND COMPOUND TERT-BUTYL 4-(2,4-DIHYDROXY-PHENYL)-4-HYDROXY-PIPERIDINE-1-CARBOXYLATE | GALDERMA RES & DEV (FR) | 2017-03-22 | — | — | EP | disclosed |
| EP-2509945-B1 | 4-(AZACYCLOALKYL)-BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RES & DEV (FR) | 2014-03-05 | — | — | EP | disclosed |
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-12-20 | — | — | US | disclosed |
| EP-2509945-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | Galderma Research & Development (FR) | 2012-10-17 | — | — | EP | disclosed |
| WO-2011070080-A1 | 4- (AZACYCLOALKYL) -BENZENE-1, 3 -DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2011-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323012-A1 | 4-(AZACYCLOALKYL) -BENZENE-1,3-DIOL DERIVATIVES AS TYROSINASE INHIBITORS AND THEIR SYNTHESIS AND USE THEREOF | TYR, DDT, TH | YAP1 1959/4885TACR1 3545/4885OPRD1 3348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.